FDA Inspection 1269921 — Revance Therapeutics, Inc.
The FDA completed an inspection of Revance Therapeutics, Inc. on May 1, 2025 in Moffett Field, CA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- May 1, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Moffett Field, CA (United States)